Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Oct, 2018 | Pages:
90 | Publisher: Grand View Research
Industry: Healthcare | Report Format: Electronic (PDF)
The global artemisinin combination therapy (ACT) market size is expected to reach USD 697.9 million by 2025, according to a new report by Grand View Research, Inc., progressing at a CAGR of 8.5% during the forecast period. Rising adoption rate of ACTs coupled with growing government initiatives to combat malaria epidemic is anticipated to stoke the growth of the market. Furthermore, expanding pipeline and new product approvals are driving the market. Currently, 6 ACTs are recommended by WHO for the treatment of uncomplicated malaria, which are Artemether-Lumefantrine (AL), artesunate-amodiaquine, Artesunate-Mefloquine (AS-AQ), Dihydroartemisinin-Piperaquine (DHA-PPQ), Artesunate-Sulfadoxine-Pyrimethamine (AS-SP), and Pyronaridine-Artesunate (PR-AS). Some of the benefits provided by ACTs are high efficacy and reduced likelihood of developing resistance. Over the years, access to artemisinin combination therapy has expanded considerably. In 2016, ACTs were used as first-line treatment in almost 80 countries. Increasing R & D initiatives by pharma-emerging countries such as India and China are revving up the adoption rate of ACTs. Rising demand from malaria endemic countries such as Kenya, Uganda, Nigeria, and Congo is poised to augment the market. Pipeline for new antimalarial drugs is widening and some of them have been introduced recently. These are some of the factors that are propelling the ACT market. WHO states the necessity for treating uncomplicated malaria, the most serious form of the disease, with ACTs as they are the best treatment available. ACTs are recommended over other treatments including Sulfadoxine-pyrimethamine, chloroquine, and artemisinin monotherapies, because parasites have developed resistance to these medicines. Malaria is one of the most distressing diseases across the globe with more than 200 million new cases reported each year. According to Medicines Malaria Venture (MMV), a total of 445,000 deaths were caused by malaria worldwide in 2016. Malaria epidemic is continuing to increase globally and climate change is projected to fuel the trend. Further key findings from the report suggest: • AL was the largest segment in 2017 due to the fact that it was the first ACT to be marketed and prequalified by WHO for its efficacy, safety, and quality. It is available in more than 60 countries and is the only ACT approved by U.S. FDA • MEA held the largest share in the market for ACTs due to growing initiatives by government and non-government organizations to raise awareness • Asia Pacific also held a prominent position in the market owing to factors such as large production base of artemisinin herbs coupled with rising access to ACT in this region • Major players operating in the market are Novartis, Sanofi, Cipla, Ajanta Pharma, Ipca Laboratories, Guilin Pharmaceuticals, and KPC Pharmaceuticals • Key players are adopting different strategies to increase their market share such as increasing geographic presence, R & D, new product development, and indication extension.
Table of Contents
Chapter 1 Research Methodology & Scope
1.1 Information Procurement
1.1.1 Purchased database:
1.1.2 GVR's internal database
1.2 Research Methodology
1.3 Geographic Scope & Assumptions
1.4 Region-wise Market Calculation
1.4.1 Region-wise market: Base estimates
1.4.2 Global market: CAGR calculation
1.5 Region-based Segment Share Calculation
1.6 List of Secondary Sources
Chapter 2 Executive Summary
2.1 Market Snapshot
Chapter 3 Market Variables, Trends & Scope
3.1 Market Segmentation & Scope
3.2 Market Driver Analysis
3.2.1 Rising Demand for Artemisinin Combination Therapy (ACT)
3.2.2 Strong product pipeline
3.2.3 Rising Government Initiatives
3.3 Market restraint analysis
3.3.1 Limited number of global manufacturers
3.4 Penetration & growth prospect mapping
3.5 ACT - SWOT Analysis, By Factor (political & legal, economic and technological)
3.6 Industry Analysis - Porter's
Chapter 4 Artemisinin Combination Therapy (ACT) Market: Type Outlook
4.1 ACT market by type, movement analysis
4.2 Artemether-Lumefantrine
4.2.1 Artemether-Lumefantrine Market estimates and forecast, 2014 - 2025 (USD Million)
4.3 Artesunate-Amodiaquine
4.3.1 Artesunate-Amodiaquine Market estimates and forecast, 2014 - 2025 (USD Million)
4.4 Dihydroartemisinin-Piperaquine
4.4.1 Dihydroartemisinin-Piperaquine Market estimates and forecast, 2014 - 2025 (USD Million)
4.5 Artesunate-Mefloquine
4.5.1 Artesunate-Mefloquine Market estimates and forecast, 2014 - 2025 (USD Million)
4.6 Artesunate-Sulfadoxine-Pyrimethamine
4.6.1 Artesunate-Sulfadoxine-Pyrimethamine Market estimates and forecast, 2014 - 2025 (USD Million)
4.7 Pyronaridine-Artesunate
4.7.1 Pyronaridine-Artesunate Market estimates and forecast, 2014 - 2025 (USD Million)
Chapter 5 Artemisinin Combination Therapy (ACT) Market: Regional Outlook
5.1 ACT market share by region, 2017 & 2025 (USD Million)
5.2.1 Asia Pacific
5.2.2 China
5.2.3 India
5.2.4 Pakistan
5.2.5 Indonesia
5.2.6 Vietnam
5.2 Latin America
5.2.1 Brazil
5.2.2 Colombia
5.3 MEA
5.3.1 Nigeria
5.3.2 Democratic Republic of Congo
5.3.3 Mali
5.3.4 Uganda
5.3.5 Kenya
5.4 RoW
Chapter 6 Competitive Landscape
6.1 Strategy Framework
6.2 Market Participation Categorization
6.2.1 Company Profiles
6.2.2 KPC Pharmaceuticals, Inc
6.2.2.1 Company overview
6.2.2.2 Financial performance
6.2.2.3 Product benchmarking
6.2.2.4 Strategic initiatives
6.2.3 Guilin Pharmaceutical Co., Ltd
6.2.3.1 Company overview
6.2.3.2 Financial performance
6.2.3.3 Product benchmarking
6.2.3.4 Strategic initiatives
6.2.4 Sanofi
6.2.4.1 Company overview
6.2.4.2 Financial performance
6.2.4.3 Product benchmarking
6.2.4.4 Strategic initiatives
6.2.5 Desano Inc.
6.2.5.1 Company overview
6.2.5.2 Financial performance
6.2.5.3 Product benchmarking
6.2.5.4 Strategic initiatives
6.2.6 Calyx Chemicals & Pharmaceutical Ltd.
6.2.6.1 Company overview
6.2.6.2 Financial performance
6.2.6.3 Product benchmarking
6.2.6.4 Strategic initiatives
6.2.7 Mylan N.V
6.2.7.1 Company overview
6.2.7.2 Financial performance
6.2.7.3 Product benchmarking
6.2.7.4 Strategic initiatives
6.2.8 Novartis AG
6.2.8.1 Company overview
6.2.8.2 Financial performance
6.2.8.3 Product benchmarking
6.2.8.4 Strategic initiatives
6.2.9 DENK PHARMA GmbH & Co.KG
6.2.9.1 Company overview
6.2.9.2 Financial performance
6.2.9.3 Product benchmarking
6.2.9.4 Strategic initiatives
6.2.10 Hovid-Integrated Global Pharmaceutical Partner
6.2.10.1 Company overview
6.2.10.2 Financial performance
6.2.10.3 Product benchmarking
6.2.10.4 Strategic initiatives
6.2.11 Ipca Laboratories Ltd.
6.2.11.1 Company overview
6.2.11.2 Financial performance
6.2.11.3 Product benchmarking
6.2.11.4 Strategic initiatives
6.2.12 Shelys Africa Pharmaceuticals Ltd.
6.2.12.1 Company overview
6.2.12.2 Financial performance
6.2.12.3 Product benchmarking
6.2.12.4 Strategic initiatives
6.2.13 Cipla Inc.
6.2.13.1 Company overview
6.2.13.2 Financial performance
6.2.13.3 Product benchmarking
6.2.13.4 Strategic initiatives
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
